TY - JOUR
T1 - Proteomic analysis of Waldenstrom macroglobulinemia
AU - Hatjiharissi, Evdoxia
AU - Ngo, Hai
AU - Leontovich, Alexey A.
AU - Leleu, Xavier
AU - Timm, Michael
AU - Melhem, Mona
AU - George, Diane
AU - Lu, Ganwei
AU - Ghobrial, Joanna
AU - Alsayed, Yazan
AU - Zeismer, Steven
AU - Cabanela, Miguel
AU - Nehme, Alex
AU - Jia, Xiaoying
AU - Moreau, Anne Sophie
AU - Treon, Steven P.
AU - Fonseca, Rafael
AU - Gertz, Morie A.
AU - Anderson, Kenneth C.
AU - Witzig, Thomas E.
AU - Ghobrial, Irene M.
PY - 2007/4/15
Y1 - 2007/4/15
N2 - To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKα. Other proteins up-regulated by >1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by >2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics.
AB - To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKα. Other proteins up-regulated by >1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by >2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=34248571776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248571776&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-06-3089
DO - 10.1158/0008-5472.CAN-06-3089
M3 - Article
C2 - 17440091
AN - SCOPUS:34248571776
SN - 0008-5472
VL - 67
SP - 3777
EP - 3784
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -